Press Releases

Year

March 14, 2024

Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN CARLOS, Calif. , March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth

February 26, 2024

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024

– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced skin inflammation model – SAN CARLOS, Calif. , Feb.

February 12, 2024

Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition

– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition – – AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif. , Feb. 12, 2024 (GLOBE NEWSWIRE) -- Allakos Inc.

January 16, 2024

Allakos Announces a Restructuring to Focus on Development of AK006

Existing cash to fund planned ongoing operations into mid-2026 AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteers a randomized, double-blind, placebo-controlled trial in patients with CSU a

January 16, 2024

Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

– Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif. , Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc.

Investors

Press Releases

(Common Stock)

Investor Toolkit